When it comes to payer management strategies for various anti-inflammatory treatments, a popular tactic is step therapy: specifying which drug or drugs are first-line treatments that patients must try before they can move on to another therapy. As payers try to get a handle on the growing — and costly — array of biologics approved for ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, some have begun stipulating the specific length of time patients need to be on a particular drug before they can step to the next drug.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.